Moderna expects annual cash costs of $4 billion to $4.5 billion from 2027 through 2030, primarily driven by increased investment in oncology. The company highlighted intismeran, its personalized melanoma vaccine, and cancer antigen therapies as foundational opportunities. Moderna is working with Merck toward commercializing intismeran in the U.S. and has a Massachusetts facility on track to support a potential launch.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
